Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
10monon MSN
Viking Therapeutics targets Phase 3 trials for VK2735 in Q2 2025 amid strong clinical progress
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase ...
SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...
Hosted on MSN
Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial
We recently compiled a list of 11 Best Future Stocks to Buy Now. Viking Therapeutics, Inc. stands third on our list. Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company ...
Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, which was the primary endpoint in VOYAGE. Importantly, patients receiving VK2809 continued to ...
VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone beta receptor (TRβ) that possesses selectivity for liver tissue, as well as the beta receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback